European Hospital Financing Reform - Developments and Business Implications

1. Executive Summary

2. Introduction

3. Healthcare Structures in Europe

3.1 Belgium and the Netherlands

3.2 France

3.3 Germany

3.4 Italy

3.5 United Kingdom

3.6 Scandinavia

3.7 Spain

4. Hospital Financing and the shift to DRG-based reimbursement for services

4.1 Benelux

Legislative reform and business implications

4.2 France

Legislative reform and business implications

4.3 Germany

Legislative reform and business implications

4.4 Italy

Legislative reform and business implications

4.5 United Kingdom

Legislative reform and business implications

4.6 Sweden

Legislative reform and business implications

5. The impact of DRGs on reimbursement in selected disease/treatment areas

5.1 Implantable cardioverter defibrillators

5.1.1 ICD therapy in the treatment of arrhythmia and complications

5.1.2 The role of ICDs in prophylaxis of SCD

5.1.3. Cost-effectiveness assessments

5.1.4 DRG and reimbursement impact on ICD implantation rates-US Recommendations

5.1.5. European ICD Implant Rates

5.2 Drug-Eluting Stents

5.2.1 Creation of new DRGs to cover stent reimbursement and encourage utilization

5.3 End stage renal disease (ESRD)

5.3.1 Prevalence and socio-economic aspects of chronic kidney disease

5.3.2 Home vs Hospital Haemodialysis – an assessment of UK guidelines

6. Health Technology Assessment (HTA) – its expanding role in medical device diffusion.

6.1 HTA activity in Europe

6.1.1 Benelux

6.1.2 France

6.1.3 Germany

6.1.4 Italy

6.1.5 Spain

6.1.6 United Kingdom

6.1.7 Scandinavia

6.2 Relevant case studies – The NICE approach and impact

7. The anticipated impact of DRG implementation in Germany

7.1 DRGs in the USA and Australia – Any lessons to be learnt for device manufacturers?

8. Corporate Strategies – Positioning in an era of increasing reform